Hepatitis Monthly

Published by: Kowsar

Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD)

Zahra Dehnavi 1 , Farkhonde Razmpour 2 , Mahmoud Belghaisi Naseri 1 , Mohsen Nematy 3 , Seyed Ali Alamdaran 4 , Hassan Ali Vatanparast 5 , Mohsen Azimi Nezhad 6 , Bita Abbasi 4 and Azita Ganji 7 , *
Authors Information
1 MSc Student of Nutrition Science, Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
2 MD PhD Candidate in Nutrition Department of Clinical Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
3 PhD Associated Professor in Nutrition Science, Department of Biochemistry and Nutrition, Endoscopic and Minimally Invasive Surgery and Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran
4 MD Associated Professor of Radiology, Faculty of Medicine, Department of Radiology, Mashhad University of Medicine Sciences (MUMS), Mashhad, Iran
5 MD PhD Associated Professor in Nutrition Science, College of Pharmacy and Nutrition, School of Public Health, Saskatchewan University of Health Sciences, Saskatchewan, Canada
6 MD PhD Assistant Professor of Medical Genetics, Department of Basic Medicine Sciences, Neyshabur University of Medical Sciences (NUMS), Neyshabur, Iran
7 MD Assistant Professor of Gastroenterology, Gastroenterology and Hepatology Research Center, Mashhad University of Medicine Sciences (MUMS), Mashhad, Iran
Article information
  • Hepatitis Monthly: February 2018, 18 (2); e63227
  • Published Online: January 24, 2018
  • Article Type: Research Article
  • Received: October 24, 2017
  • Revised: November 27, 2017
  • Accepted: December 27, 2017
  • DOI: 10.5812/hepatmon.63227

To Cite: Dehnavi Z, Razmpour F, Belghaisi Naseri M, Nematy M, Alamdaran S A, et al. Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD), Hepat Mon. 2018 ; 18(2):e63227. doi: 10.5812/hepatmon.63227.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
5. Conclusions
Acknowledgements
Footnotes
References
  • 1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31. doi: 10.1056/NEJMra011775. [PubMed: 11961152].
  • 2. Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon. 2013;13(5):9270. doi: 10.5812/hepatmon.9270. [PubMed: 23930133].
  • 3. Oh H, Jun DW, Saeed WK, Nguyen MH. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol. 2016;22(3):327-35. doi: 10.3350/cmh.2016.0049. [PubMed: 27729634].
  • 4. Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13(5):9248. doi: 10.5812/hepatmon.9248. [PubMed: 23922564].
  • 5. Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2(2):135-44. doi: 10.1016/S0973-6883(12)60102-9. [PubMed: 25755422].
  • 6. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, et al. Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran. Int J Organ Transplant Med. 2016;7(3):149-60. [PubMed: 27721961].
  • 7. Zheng RD, Chen ZR, Chen JN, Lu YH, Chen J. Role of Body Mass Index, Waist-to-Height and Waist-to-Hip Ratio in Prediction of Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract. 2012;2012:362147. doi: 10.1155/2012/362147. [PubMed: 22701476].
  • 8. Jager S, Jacobs S, Kroger J, Stefan N, Fritsche A, Weikert C, et al. Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One. 2015;10(4):124749. doi: 10.1371/journal.pone.0124749. [PubMed: 25902304].
  • 9. Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol. 2016;22(32):7236-51. doi: 10.3748/wjg.v22.i32.7236. [PubMed: 27621571].
  • 10. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36(1):13-20. doi: 10.1016/j.clinre.2011.08.001. [PubMed: 21920839].
  • 11. Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, et al. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(10):3023-30. doi: 10.3748/wjg.v22.i10.3023. [PubMed: 26973398].
  • 12. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201-4. doi: 10.1016/j.cgh.2012.12.031. [PubMed: 23353640].
  • 13. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. doi: 10.1186/1471-230X-6-33. [PubMed: 17081293].
  • 14. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology. 2011;54(1):145-52. doi: 10.1002/hep.24356. [PubMed: 21488080].
  • 15. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(2):475-85. doi: 10.3748/wjg.v20.i2.475. [PubMed: 24574716].
  • 16. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40(5):371-8. doi: 10.1016/j.dld.2007.10.019. [PubMed: 18083083].
  • 17. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-62. doi: 10.1002/hep.23312. [PubMed: 20101745].
  • 18. Desai NK, Harney S, Raza R, Al-Ibraheemi A, Shillingford N, Mitchell PD, et al. Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients. J Pediatr. 2016;173:160-164 e1. doi: 10.1016/j.jpeds.2016.03.021. [PubMed: 27039224].
  • 19. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56(7):968-73. doi: 10.1136/gut.2006.111302. [PubMed: 17255218].
  • 20. Huang BX, Zhu MF, Wu T, Zhou JY, Liu Y, Chen XL, et al. Neck circumference, along with other anthropometric indices, has an independent and additional contribution in predicting fatty liver disease. PLoS One. 2015;10(2):118071. doi: 10.1371/journal.pone.0118071. [PubMed: 25679378].
  • 21. Subramanian V, Johnston RD, Kaye P, Aithal GP. Regional anthropometric measures associated with the severity of liver injury in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;37(4):455-63. doi: 10.1111/apt.12198. [PubMed: 23293873].
  • 22. Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep. 2014;2(5):633-6. doi: 10.3892/br.2014.309. [PubMed: 25054002].
  • 23. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol. 2014;6(5):263-73. doi: 10.4254/wjh.v6.i5.263. [PubMed: 24868320].
  • 24. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102(12):2716-7. doi: 10.1111/j.1572-0241.2007.01520.x. [PubMed: 18042105].
  • 25. Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One. 2015;10(3):120443. doi: 10.1371/journal.pone.0120443. [PubMed: 25781622].
  • 26. Monteiro PA, Antunes Bde M, Silveira LS, Christofaro DG, Fernandes RA, Freitas Junior IF. Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. BMC Pediatr. 2014;14:25. doi: 10.1186/1471-2431-14-25. [PubMed: 24476029].
  • 27. Brunt EM. Nonalcoholic steatohepatitis. Seminars in liver disease. Thieme Medical Publishers, Inc; 2004. p. 3-20.
  • 28. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8. [PubMed: 7382552].
  • 29. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209-18. doi: 10.1172/JCI24282. [PubMed: 15690074].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments